Hypoglycaemia, chronic kidney disease and death in type 2 diabetes: the Hong Kong diabetes registry

Alice PS Kong1†, Xilin Yang2†, Andrea Luk1,3, Kitty KT Cheung1, Ronald CW Ma1, Wing Yee So1, Chung Shun Ho4, Michael HM Chan4, Risa Ozaki1, Chun Chung Chow1, Nicola Brown3 and Juliana CN Chan1,3,5,6*

Abstract

Background: In patients with type 2 diabetes, chronic kidney disease (CKD) is associated with increased risk of hypoglycaemia and death. Yet, it remains uncertain whether hypoglycaemia-associated mortality is modified by CKD.

Methods: Type 2 diabetic patients, with or without CKD at enrolment were observed between 1995 and 2007, and followed up till 2009 at hospital medical clinics. We used additive interaction, estimated by relative excess risk due to interaction (RERI) and attributable proportion due to interaction (AP) to examine possible synergistic effects between CKD and severe hypoglycaemia (defined as hospitalisations due to hypoglycaemia in the 12 months prior to enrolment) on the risk of death.

Results: In this cohort of 8,767 type 2 diabetic patients [median age: 58 (interquartile range: 48 to 68) years; disease duration: 5 (1 to 11) years, men: 47.0%], 1,070 (12.2%) had died during a median follow-up period of 6.66 years (3.42-10.36) with 60,379 person-years. Upon enrolment, 209 patients had severe hypoglycaemia and 194 developed severe hypoglycaemia during follow-up (15 patients had both). In multivariable analysis and using patients without severe hypoglycaemia nor CKD as the referent group (683 deaths in 7,598 patients), severe hypoglycaemia alone (61 deaths in 272 patients) or CKD alone (267 deaths in 781 patients) were associated with increased risk of death [Hazard ratio, HR: 1.81 (95%CI: 1.38 to 2.37) and 1.63 (1.38 to 1.93) respectively]. Having both risk factors (59 deaths in 116 patients) greatly enhanced the HR of death to 3.91 (2.93 to 5.21) with significant interaction (RERI: 1.46 and AP: 0.37, both p-values < 0.05).

Conclusions: Severe hypoglycaemia and CKD interact to increase risk of death in type 2 diabetes patients.

Background

When glycaemic control is targeted to a glycated haemoglobin (HbA1c) of 7% in patients suffering from type 2 diabetes, microvascular and macrovascular complications and all-cause mortality is reduced [1]. Large scale randomized controlled trials including the ADVANCE (Action in Diabetes and Vascular disease: preterAx and diamicroN modified release Controlled Evaluation) [2], ACCORD (Action to Control Cardiovascular Risk in Diabetes) [3] and VADT (Veteran Affairs Diabetes Trial) [4] have been conducted to determine whether intensive lowering of HbA1c to less than 7% would further improve cardiovascular outcomes [2-4]. However, the results from the ACCORD study rekindled the debate on risk-benefit ratio of these intensive strategies with the premature discontinuation of the intensive blood-glucose lowering arm in the ACCORD Study [3,5,6]. Subsequent analysis of both the ACCORD and ADVANCE Study revealed that while intensive glycaemic control increased the risk of severe hypoglycaemia which was associated with increased risk of death, the hazard ratios (HR) were in fact lower in the intensively-treated group, suggesting that intensive monitoring with prompt corrective actions might mitigate the potential harm of intensive blood glucose lowering [6,7].

However, due to volunteer effects and to the unique environment of a randomized controlled trial setting,
the applicability of these findings to a real world setting remains uncertain. To date, there is a paucity of long-term data with adequate documentation of confounders to allow detailed analysis of the causes and consequences of hypoglycaemia in type 2 diabetes [8]. To this end, renal dysfunction is a potential risk amplifier for death associated with hypoglycaemia. Microalbuminuria is known to be the earliest clinical evidence of diabetic nephropathy and up to 20-40% of diabetic patients progress to overt nephropathy if left untreated [9]. In Asia, micro- and macroalbuminuria are common in type 2 diabetic patients, affecting 50-60% of patients with type 2 diabetes [10] while about 16% of type 2 diabetic patients suffer from chronic kidney disease (CKD) [11].

Given the high rates of diabetic nephropathy (usually considered as nephropathy with or without CKD) and CKD (based on eGFR alone) in Asian populations and the high risk of hypoglycaemia and clinical outcomes in CKD patients, we questioned whether the co-occurrence of these conditions will further increase the risk of future events. In a prospective registry with detailed documentation of risk factors, complications, drug use and clinical outcomes, we explored the prognostic significance of CKD on incident severe hypoglycaemia and the interactive effects of prevalent CKD and severe hypoglycaemia on future risk of clinical outcomes.

Methods

We retrospectively analysed the data of a prospective observational study of type 2 diabetic patients enrolled into the Hong Kong Diabetes Registry. Upon enrolment, diabetic patients undergo comprehensive assessments which follow a structured protocol whose methodology has been described previously [11-14]. Briefly, the Hong Kong Diabetes Registry was established in 1995 at the Prince of Wales Hospital, which serves a population of over 1.2 million. Since 1995, diabetic patients attending medical clinics at the Prince of Wales Hospital can be referred to the Diabetes Centre for comprehensive assessment based on the European DIABCARE protocol [15]. Hong Kong has a heavily subsidized healthcare system, so the vast majority of patients with chronic illnesses, including diabetes, are managed in public hospitals governed by the Hospital Authority (HA), which provide for 95% of the total hospital bed-days in Hong Kong [12]. Once the participants are entered into the Registry, their outcomes including hospital admissions will be monitored until the death of the patient [11-14]. From 1995 to the 31st December 2007, 10,129 patients have been enrolled into the cohort. After excluding 417 patients with type 1 diabetes (including missing data on classification of diabetes type), and 945 with missing variables used in the analysis, 8,767 patients were included in this analysis.

The enrolled patients periodically underwent a comprehensive 4-hour assessment for quality assurance including interview by diabetes nurses, anthropometric measurements, blood and urine tests, fundus examination and podiatry assessment. After 8 hours of overnight fast, blood was sampled for assay of fasting plasma lipids [total cholesterol (TC), HDL-C, triglyceride (TG) and calculated LDL-C], glucose, HbA1c, renal and liver function tests. We used spot urinary albumin: creatinine ratio (ACR) to define albuminuria (ACR ≥ 2.5 mg/mmol in men and ≥3.5 mg/mmol in women). The abbreviated Modification of Diet in Renal Disease Study (MDRD) formula recalibrated for Chinese [16] was used to define CKD as eGFR < 60 ml/min/1.73 m² [17]. All laboratory analyses were performed using standard methods in the Department of Chemical Pathology of the Prince of Wales Hospital. The laboratory is accredited by the Australian National Association of Testing Authorities. Informed written consent was obtained from all participants and the study was approved by the Chinese University of Hong Kong Clinical Research Ethics Committee prior to its initiation.

Severe hypoglycaemia was defined as one or more hospitalisations due to hypoglycaemia 12 months prior to enrolment (‘at enrollment’), in order not to miss events and subjects with characteristics relevant to this present analysis, or during the follow-up period [14], as defined from enrolment to death or 31st January, 2009. Using the same definition for severe hypoglycaemia, we had previously reported that severe hypoglycaemia identified vulnerable type 2 diabetic patients who were at risk for premature death and were associated with cancer subphenotypes [14]. We ascertained all clinical outcomes using the HA Central Computer Management System (CMS), which records diagnoses of all hospital discharges, including mortality based on the International Classification of Diseases, Ninth Revision (ICD-9). The mortality data was cross-checked with the Hong Kong Death Registry and the cause of death was defined by the principal discharge diagnosis.

Statistical analysis

The Statistical Analysis System (Release 9.30) was used to perform all analyses (SAS Institute Inc., Cary, NC, USA) unless specified. Follow-up time was calculated as the period in years from the first enrolment to the date of death or 31st January 2009, whichever came first. All data were expressed as mean ± SD or median (interquartile range, IQR). Cox proportional hazard regression was used to obtain hazard ratio (HR) and 95% confidence interval (CI) of variables of interest. We used the Yes/No coding scheme for all major drug use at enrolment. Immortal time is defined as the period of time without exposure to hypoglycaemia from the point of enrolment.
into the study to the date of first hospitalization due to hypoglycemia during the follow-up period in this study. This however, may introduce immortal time bias [18,19]. In this regard, we performed a validation study of various methods to cope with immortal time bias and found that removal of immortal time led to the least inflated hazard ratio [20]. Thus, in this study, we excluded 896.8 person-years of immortal time from the analysis by moving the commencement point of follow-up from date of enrolment to the time of first hospitalization due to hypoglycemia during follow-up. For patients with severe hypoglycemia at enrolment, the immortal period was considered statistically significant. The Statistical Package for Social Sciences version 16 (SPSS, Chicago, US) was used to obtain the adjusted plot of cumulative mortality stratified by hypoglycemia and CKD and their combination over time.

**Results**

The median age of the cohort was 58 years (IQR:48–68) with a disease duration of 5 [1–11] years. During a median follow-up period of 6.66 (3.42–10.36) years with 60,379 person-years, 1,070 patients had died with a mortality rate of 17.7 (16.7–18.8) per 1000-person-years. The deceased were older, more likely to be men, ex/current smokers and alcohol drinkers, had longer disease duration, higher SBP, HbA1c, LDL-C and lower BMI and HDL-C than those who survived. They were also more likely to have history of CVD and cancers (all p <0.05), poorer renal function (higher ACR, lower eGFR) and more frequent severe hypoglycemia events (both at enrolment and during follow-up) (p <0.0001) (Table 1).

After excluding 209 patients who had documented hypoglycemia upon enrollment, 179 patients developed hypoglycemia with an event rate of 3.02(95%CI: 2.57–3.46) per 1,000 person-years. In this cohort, 897 patients (10.2%) had CKD at enrollment, amongst whom, 116 (12.9%) had hospitalizations due to hypoglycemia (50 at enrollment, 60 during follow-up and 6 had events both at enrollment and during follow-up). In patients without CKD (n = 7870), 272(3.46%) had hospitalizations due to hypoglycemia (144 at enrollment, 119 during follow-up and 9 with events both at enrollment and during follow up) with higher rate of hypoglycemia in patients with CKD than those without (p <0.0001).

In multivariable analysis, severe hypoglycemia predicted mortality among patients with CKD with a HR of 2.63 (1.95 to 3.55) and to a lesser extent, among those without CKD [1.72(1.31 to 2.26)] (Table 2). After adjusting for confounders, CKD enhanced the HR of severe hypoglycemia for all-cause mortality from 1.81(1.38 to 2.37) to 3.91 (2.93 to 5.21) (Table 3) with significant additive interaction between hypoglycemia and CKD (RERI: 1.46 (0.31 to 2.61, p = 0.0126); AP: 0.37(0.17 to 0.58, p = 0.0177) (Additional file 2: Table S2). From 1 December 1996 to 30 July 2005, 52.7% (n = 4618) of the diabetic patients have documented use of sulfonylurea and after further adjustment for the use of sulfonylurea during this period, this had little impact on the HRs.

Figure 1 shows the multivariable cumulative mortality of patients categorized by hypoglycemia and CKD with the highest mortality rate in those with both CKD and hypoglycemia.
Among the 1,070 deaths, the major causes were cancer (23.4%, n = 250), CVD (22.9%, n = 245), respiratory disease (15.1%, n = 162) and renal disease (13.6%, n = 146). After adjustment for confounders, CKD was an independent predictor for cardiovascular [1.54 (1.20 to 2.13)] related deaths, whereas severe hypoglycaemia was an independent predictor for renal [3.10 (1.97 to 4.89)] and cancer-related deaths [1.97 (1.26 to 3.07)] (Table 4).

**Discussion**

To our knowledge, this study is the first report on the increased risk of all-cause mortality in Chinese type 2 diabetic patients with co-occurrence of hypoglycaemia episodes and CKD in a real-world setting. Compared to patients without CKD or severe hypoglycaemia, the co-occurrence of these two risk factors markedly increased the risk of all-cause mortality by four-fold. While CKD

### Table 1 Clinical and biochemical characteristics of the study cohort

|                        | Patients who survived (n = 7697) | Patients who died (n = 1070) | P value† |
|------------------------|---------------------------------|-----------------------------|---------|
| Age, years             | Median (25th to 75th) or n(%)   | Median (25th to 75th) or n(%) | <0.0001 |
| Male gender            | 57(47–66)                       | 69(62–75)                   | <0.0001 |
| Smoking status         | Ex-smoker 1094(14.2%)           | 256(23.9%)                  | <0.0001 |
|                       | Current smoker 1310(17.0%)      | 197(18.4%)                  | <0.0001 |
| Alcohol intake         | Ex-drinker 846(11.0%)           | 206(19.3%)                  | <0.0001 |
|                       | Current drinker 720(9.4%)       | 57(19.3%)                   | <0.0001 |
| Body mass index, kg/m² | 24.9(22.6-27.6)                 | 24.2(21.8-26.6)             | <0.0001 |
| Duration of diabetes, years | 5(1-10)                  | 9(4–15)                     | <0.0001 |
| Systolic BP, mmHg      | 132(120–145)                    | 144(128–159)                | <0.0001 |
| Diastolic BP, mmHg     | 75(68–82)                       | 75(68–83)                   | 0.4583  |
| HbA1c, %               | 7.2(6.3-8.4)                    | 7.5(6.5-8.9)                | <0.0001 |
| LDL-C, mmol/L          | 2.98(2.40-3.60)                 | 3.14(2.50-3.90)             | <0.0001 |
| HDL-C, mmol/L          | 1.28(1.09-1.52)                 | 1.25(1.03-1.54)             | 0.0108  |
| Triglyceride, mmol/L   | 1.37(0.97-1.99)                 | 1.36(0.98-2.00)             | 0.6668  |
| Spot urinary ACR, mg/mmol | 1.69(2.72)                  | 13.42(2.06-120.20)         | <0.0001 |
| Prior cardiovascular disease | 972(12.6%)                 | 321(30.0%)                  | <0.0001 |
| Prior cancer           | 193(2.9%)                       | 69(6.5%)                    | <0.0001 |

**Medication use at enrollment**

- Renin-angiotensin system inhibitors: 1687(21.9%) vs. 306(28.6%) (p < 0.0001)
- Lipid lowering drugs: 1509(19.6%) vs. 170(15.9%) (p = 0.0038)
- Oral anti-diabetes drugs: 5355(69.3%) vs. 626(58.5%) (p < 0.0001)
- Insulin: 1197(15.6%) vs. 311(29.1%) (p < 0.0001)

**CKD events at baseline**

- eGFR, ml min⁻¹ 1.73 m⁻² at baseline: 105.6(86.2-126.0) vs. 79.0(51.7-104.7) (p < 0.0001)
- eGFR < 60 ml min⁻¹ 1.73 m⁻² at baseline: 57.1(7.4%) vs. 326(30.5%) (p < 0.0001)

**Major hypoglycaemia events**

- 12 months prior to enrollment: 146(1.9%) vs. 63(5.9%) (p < 0.0001)
- During follow-up only$: 122(1.6%) vs. 57(5.3%) (p < 0.0001)
- Either of them: 268(3.5%) vs. 120(11.2%) (p < 0.001)

**Abbreviations:** HbA1c, glycated haemoglobin; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; BP, blood pressure; ACR, albumin:creatinine ratio; eGFR, estimated glomerular filtration rate.

† Derived from Wilcoxon Two-Sample test or Chi-squared test where appropriate.

§ Defined as hypoglycaemia events that required hospitalisations. For patients who developed the event during follow-up, the time period from enrollment to the time of hospitalisation was removed as the immortal time period so that the follow-up started at the time of admission for hypoglycaemia. In these patients, all baseline values of continuous covariables and prior cancer and cardiovascular disease were re-estimated by treating the time of admission for hypoglycaemia as the enrollment date.
Table 2 Hazard ratios of severe hypoglycaemia and chronic kidney disease (CKD) for the risk of all-cause death in patients with type 2 diabetes

| Exposures                          | Number of death (%) | Hazard ratio | 95% CI       | P value |
|------------------------------------|---------------------|--------------|--------------|---------|
| **Independent Models**             |                     |              |              |         |
| Patients without CKD               |                     |              |              |         |
| Model 1: Hypoglycemia              | 749(9.45%)          | 3.48         | 2.68 to 4.52 | <0.0001 |
| Model 2: Hypoglycemia              | 749(9.45%)          | 1.81         | 1.38 to 2.38 | <0.0001 |
| Model 3: Hypoglycemia              | 749(9.45%)          | 1.72         | 1.31 to 2.26 | <0.0001 |
| Patients with CKD                  |                     |              |              |         |
| Model 1: Hypoglycemia              | 326(36.34%)         | 2.87         | 2.16 to 3.82 | <0.0001 |
| Model 2: Hypoglycemia              | 326(36.34%)         | 2.70         | 2.00 to 3.64 | <0.0001 |
| Model 3: Hypoglycemia              | 326(36.34%)         | 2.63         | 1.95 to 3.55 | <0.0001 |
| **Interactive Models**             |                     |              |              |         |
| Model 1                           |                     |              |              |         |
| Hypoglycemia = Yes and CKD = No    | 61(22.43%)          | 3.47         | 2.67 to 4.52 | <0.0001 |
| Hypoglycemia = No and CKD = Yes    | 267(34.19%)         | 5.70         | 4.93 to 6.57 | <0.0001 |
| Hypoglycemia = Yes and CKD = Yes   | 59(50.86%)          | 16.21        | 12.38 to 21.23 | <0.0001 |
| Hypoglycemia = No and CKD = No     | 683(8.99%)          | Reference    |              |         |
| Model 2                           |                     |              |              |         |
| Hypoglycemia = Yes and CKD = No    | 61(22.43%)          | 1.87         | 1.43 to 2.44 | <0.0001 |
| Hypoglycemia = No and CKD = Yes    | 267(34.19%)         | 1.75         | 1.49 to 2.07 | <0.0001 |
| Hypoglycemia = Yes and CKD = Yes   | 59(50.86%)          | 4.32         | 3.25 to 5.75 | <0.0001 |
| Hypoglycemia = No and CKD = No     | 683(8.99%)          | Reference    |              |         |
| Model 3                           |                     |              |              |         |
| Hypoglycemia = Yes and CKD = No    | 61(22.43%)          | 1.81         | 1.38 to 2.37 | <0.0001 |
| Hypoglycemia = No and CKD = Yes    | 267(34.19%)         | 1.63         | 1.38 to 1.93 | <0.0001 |
| Hypoglycemia = Yes and CKD = Yes   | 59(50.86%)          | 3.91         | 2.93 to 5.21 | <0.0001 |
| Hypoglycemia = No and CKD = No     | 683(8.99%)          | Reference    |              |         |

Model 1, not adjusted for other covariables at enrollment;  
Model 2, adjusted for age, sex, body mass index (BMI), smoking status, alcohol use, low-density lipoprotein cholesterol (LDL-C), high density-lipoprotein cholesterol, triglyceride, systolic blood pressure (SBP), Hba1c, duration of disease, and Ln (urinary albumin to creatinine ratio [ACR] +1), prior cardiovascular disease and prior cancer. As BMI violated the proportional hazard assumption, Cox models stratified on quartiles of BMI were used to adjust for the confounding effect of BMI;  
Model 3, further adjusted for drug use at enrollment, including lipid lowering drugs, renin-angiotensin system inhibitors, oral anti-diabetes drugs and insulin.

Table 3 Further adjustment for the use of sulfonylurea from 1 December 1996 to 30 July 2005 in model 3 of Tables 2, 3

| Exposures                                      | Number of death (%) | Hazard ratio | 95% CI       | P value |
|------------------------------------------------|---------------------|--------------|--------------|---------|
| **Independent Models**                         |                     |              |              |         |
| Patients without CKD                           |                     |              |              |         |
| Hypoglycemia                                   | 749(9.45%)          | 1.72         | 1.31 to 2.26 | <0.0001 |
| Patients with CKD                              |                     |              |              |         |
| Hypoglycemia                                   | 326(36.34%)         | 2.64         | 1.96 to 3.56 | <0.0001 |
| **Interactive Models**                         |                     |              |              |         |
| Hypoglycemia = Yes and CKD = No                | 61(22.43%)          | 1.81         | 1.38 to 2.37 | <0.0001 |
| Hypoglycemia = No and CKD = Yes                | 267(34.19%)         | 1.63         | 1.38 to 1.93 | <0.0001 |
| Hypoglycemia = Yes and CKD = Yes               | 59(50.86%)          | 3.91         | 2.93 to 5.21 | <0.0001 |
| Hypoglycemia = No and CKD = No                 | 683(8.99%)          | Reference    |              |         |

Covariables adjusted were listed in model 3 of Table 2 and ever use of sulfonylurea from 1 December 1996 to 30 July 2005.
predicted CVD-related deaths, hypoglycaemia predicted renal and cancer-related deaths.

The premature termination of ACCORD study has led to heated debates regarding the safety of tight glycaemic control and the impact of hypoglycaemia on mortality [5,6]. In the ACCORD Study, the all-cause mortality rate (mainly due to CVD) was 21% higher in the intensive treatment group (target HbA1c < 6%) compared to the standard treatment group (target HbA1c 7-7.9%) [3]. Although detailed post-hoc analysis did not reveal direct association between hypoglycaemia and CVD [6], these findings have alerted clinicians to the importance of individualizing treatment goals and strategies in order to maximize benefits and minimize harm [23].

Hitherto, the risk-benefit ratios of intensive glycaemic control in type 2 diabetes have not been sufficiently studied [8]. While intensive glycaemic control may help to reduce the risks of development of diabetes-related complications, tight control of glycaemia inevitably leads to hypoglycaemia. In diabetic patients with advanced diseases, hypoglycaemia may amplify the adverse consequences of cognitive impairment, dementia, cardiac ischemia and arrhythmia [24,25]. In the United Kingdom Prospective Diabetes Study (UKPDS), the annual rate of major hypoglycaemia, defined by symptoms requiring assistance from a third-party or medical intervention, ranged from 0.7% in patients treated with oral drugs to 1.8% in the insulin-treated patients [26]. In the ADVANCE Study, during a median follow-up period of 4 years, 231 (2.1%) patients developed severe hypoglycaemia (defined as blood glucose < 2.8 mmol/l with neurological dysfunction and third-party assistance) which was associated with 2–3 fold increased risk of microvascular complications, cardiovascular events and all-causes mortality [7].

**Additive effects between CKD and hypoglycaemia on death**

Our results, collected in a usual care setting, indicated that severe hypoglycaemia occurred in 4.4% of patients with type 2 diabetes with an annualized event rate of approximately 0.3%. After adjusting for covariables, hypoglycaemia markedly increased the risk of all-cause mortality, especially in those with CKD, which accounted for 10.2% of the cohort. Besides malnutrition and reduced gluconeogenesis (approximately one fifth of plasma glucose originated from renal gluconeogenesis), diabetic patients with CKD often have altered drug metabolism and autonomic neuropathy with hypoglycaemic unawareness, which put them at high risk of hypoglycaemia [27]. In this context, renal dysfunction is a major risk factor for drug-induced hypoglycaemia [28]. In a 15-month retrospective study reported by our group [29], among 127 type 1 and type 2 diabetic patients hospitalized due to drug-induced hypoglycaemia (which accounted for 0.5% of the total medical admissions), factors includingold age, institutionalization and renal dysfunction predicted hypoglycaemia-associated death. Many of these hypoglycaemia events were related to the use of sulphonylureas. Other researchers have reported experimental and clinical data showing that hypoglycaemia might cause arrhythmia, abnormal
Table 4 Hazard ratios of severe hypoglycaemia events and chronic kidney disease (CKD) for the risk of cause-specific death in patients with type 2 diabetes

| Causes of death        | Number of death (%) | Hazard ratio | 95% CI        | P value  |
|------------------------|---------------------|--------------|---------------|----------|
| **Cardiovascular disease** |                     |              |               |          |
| Model 1                |                     |              |               |          |
| Hypoglycemia events    | 14(3.61%)           | 1.48         | 0.86 to 2.54  | 0.1619   |
| CKD                    | 83(9.25%)           | 7.15         | 5.45 to 9.38  | <0.0001  |
| Model 2                |                     |              |               |          |
| Hypoglycemia events    | 0.99                | 0.57 to 1.71 | 0.9603        |          |
| CKD                    | 1.63                | 1.19 to 2.23 | 0.0021        |          |
| Model 3                |                     |              |               |          |
| Hypoglycemia events    | 0.99                | 0.57 to 1.72 | 0.9790        |          |
| CKD                    | 1.54                | 1.20 to 2.13 | 0.0081        |          |
| **Renal disease**      |                     |              |               |          |
| Model 1                |                     |              |               |          |
| Hypoglycemia events    | 26(6.70%)           | 4.27         | 2.76 to 6.61  | <0.0001  |
| CKD                    | 88(9.81%)           | 20.92        | 14.79 to 29.58 | <0.0001  |
| Model 2                |                     |              |               |          |
| Hypoglycemia events    | 3.20                | 2.03 to 5.02 | <0.0001       |          |
| CKD                    | 3.47                | 2.35 to 5.15 | <0.0001       |          |
| Model 3                |                     |              |               |          |
| Hypoglycemia events    | 3.10                | 1.97 to 4.89 | <0.0001       |          |
| CKD                    | 3.42                | 2.29 to 5.11 | <0.0001       |          |
| **Respiratory disease**|                     |              |               |          |
| Model 1                |                     |              |               |          |
| Hypoglycemia events    | 13(3.35%)           | 2.29         | 1.29 to 4.07  | 0.0048   |
| CKD                    | 45(5.02%)           | 5.19         | 3.65 to 7.39  | <0.0001  |
| Model 2                |                     |              |               |          |
| Hypoglycemia events    | 1.24                | 0.69 to 2.23 | 0.4741        |          |
| CKD                    | 1.54                | 1.03 to 2.31 | 0.0358        |          |
| Model 3                |                     |              |               |          |
| Hypoglycemia events    | 1.21                | 0.67 to 2.18 | 0.5235        |          |
| CKD                    | 1.44                | 0.95 to 2.17 | 0.0845        |          |
| **All-site cancer**    |                     |              |               |          |
| Model 1:               |                     |              |               |          |
| Hypoglycemia events    | 24(6.19%)           | 3.21         | 2.10 to 4.92  | <0.0001  |
| CKD                    | 28(3.12%)           | 1.39         | 0.94 to 2.08  | 0.1030   |
| Model 2                |                     |              |               |          |
| Hypoglycemia events    | 2.09                | 1.34 to 3.26 | 0.0011        |          |
| CKD                    | 1.00                | 0.64 to 1.54 | 0.9805        |          |
| Model 3                |                     |              |               |          |
| Hypoglycemia events    | 1.97                | 1.26 to 3.07 | 0.0027        |          |
| CKD                    | 0.92                | 0.59 to 1.44 | 0.7192        |          |

Adjustment schemes for models 1 to 3 were the same as listed in Tables 2 and 3.
Hypoglycaemia and all-cause deaths

In our analysis, type 2 diabetic patients who died before the censor date were more likely to use insulin and renin-angiotensin system (RAS) inhibitors. This pattern of drug usage was compatible with long disease duration, progressive beta cell failure and high cardiovascular-renal risk in these subjects. Since many patients were enrolled in the 1990's when the beneficial effects resulted from the utility of these drugs was less well documented, the usage of RAS inhibitors and statin was relatively low which might have contributed to the high event rates in this cohort. In our previous analysis [12], we reported that urinary ACR, eGFR and albuminuria predicted all-cause death. The combination of renal dysfunction and insulin use put patients at high risk for hypoglycaemia if they were not monitored closely. Of note, over 20% of our patients died of cancer, a proportion similar to CVD-related deaths. Thus, multiple organ dysfunction, abnormal metabolic milieu and malnutrition, often associated with CKD and cancer [34,35], might contribute to the additive interactions between CKD and hypoglycaemia on all-cause death in our cohort. In support of these findings, we also found that while CKD predicted CVD-related deaths, hypoglycaemia predicted cancer and renal-related deaths. Thus, despite the theoretical risk of hypoglycaemia for CVD, our study was only able to confirm the risk association of hypoglycaemia with all-cause but not CVD-related deaths, which is in agreement with the ACCORD study. Taken together, we argue that hypoglycaemia might be a marker of frailty and multiple organ dysfunction including cancer which should alert clinicians to reassess the clinical status and screen for silent conditions such as CKD and occult cancer. To this end, the 1.3-3 fold increased risk for multiple morbidities including cancer in diabetes is now well recognized [36,37] and support the frequent co-occurrence of hypoglycaemia, CKD and non-CVD deaths in our analysis.

Limitations

Firstly, in this real-world dataset, all clinical outcomes were ascertained by ICD-9 codes, which might contain errors due to misclassification and/or under-coding. However, validation analysis suggested that the estimated predictive value of administrative data for clinical outcomes could be as high as 95% for acute myocardial infarction and stroke [38,39]. Secondly, we only included severe hypoglycaemic episodes requiring hospitalizations, which were specific but not sensitive indicators of these adverse events. Since our database did not systematically capture minor hypoglycaemia not requiring admission, under-estimation of true rates of hypoglycaemia was likely. Although our analysis did not confirm the risk association between severe hypoglycaemia and CVD-related deaths, it remained plausible that multiple minor hypoglycaemic episodes could have cumulative adverse effects on cardiovascular and cerebrovascular functions with direct or indirect impacts on mortality. Thirdly, we captured and adjusted the drug use at baseline but did not have data on changes of concomitant medications and metabolic profiles during the whole follow-up. Fourthly, only eGFR at baseline was used to estimate the occurrence of CKD events because we did not measure eGFR on a regular basis among all the patients in our cohort. Thus, some CKD events during follow-up had been missed.

Conclusions

Using a real-world registry, we confirmed the independent and interactive effects of CKD and severe hypoglycaemia on all-cause death, with hypoglycaemia independently predicting cancer and renal-related death. These findings added to the growing body of literature on the vulnerability of diabetic patients with CKD and called for comprehensive assessment in patients with hypoglycaemia to screen for silent conditions such as CKD and cancer as well as review of treatment regimens to reduce the risk of hypoglycaemia in patients with these comorbidities.

Ethical approval

The Joint Chinese University of Hong Kong and New Territories East Cluster Clinical Research Ethics Committee.

Additional files

Additional file 1: Table S1. Estimated partial regression coefficients of age and duration of diabetes for metabolic indicators at baseline.

Additional file 2: Table S2. Additive interaction of hypoglycaemia events and chronic kidney disease for all-cause death in type 2 diabetes.

Competing interests

We declare that we have no conflicts of interest except for JC, who has received honorarium from Bayer, Boehringer Ingelheim, Daiichi-Sankyo, Eli-Lilly, GlaxoSmithKline, Merck Sharp & Dohme, Merck Serono, Pfizer, Astra
Zenegro, Sanofi, Novo-nordisk and/or Bristol-Myers Squibb for consultancy or delivery of lectures; AK who has received honorarium for consultancy or delivery of lectures from AstraZeneca, Novo-nordisk, Eli-Lilly, Merck Serono, Pfizer, Jansen, Sanofi and Nestle; and RM who has received honorarium for consultancy or delivery of lectures from AstraZeneca, Boehringer Ingelheim, Danone, Eli Lilly, Nestle, Pfizer and Sanofi. The proceeds have been partially donated to the Chinese University of Hong Kong, American Diabetes Association and other charity organizations to support diabetes research and education. The Chinese University of Hong Kong has received research grants from the above companies. Other authors declared no conflict of interest with this manuscript.

Authors’ contributions
AK, KY, RO, NB and JC contributed to the analysis and preparation of the manuscript. AK, AL, KC, RM, WS, CH, MC, RO, CC and JC contributed to the collection of the data. JC, the corresponding author, accepts full responsibility for the content of this paper. All authors read and approved the final manuscript.

Acknowledgements
We thank all doctors and nurses at the Diabetes Mellitus and Endocrine Centre, Prince of Wales Hospital for recruiting and managing these patients. The study was partially supported by the Hong Kong Foundation for Research and Development in Diabetes and Liao Wun Yuk Diabetes Memorial Research Fund of the Chinese University of Hong Kong.

Author details
1. Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, SAR, China. 2. Department of Epidemiology and Biostatistics, School of Public Health, Tianjin Medical University, Tianjin, China. 3. Asia Diabetes Foundation, Shatin, China. 4. Department of Chemical Pathology, Shatin, China. 5. Li KaShing Institute of Health Sciences, Shatin, China. 6. Hong Kong Institute of Diabetes and Obesity, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, SAR, China.

Received: 25 February 2014 Accepted: 10 June 2014 Published: 13 June 2014

References
1. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA: 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008, 359:1577–89.
2. Patel A, MacMahon S, Chalmers J, et al: Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007, 370(9590):629–40.
3. Gerstein HC, Miller ME, Byington RP, et al: Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 359:2545–59.
4. Dukworth W, Abraira C, Montor D, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCaren M, Vitek ME, Henderson WG, Huang GD, Abraira C, Duckworth WC, Paul C, Arca D, Cai A, Martinez Zolotor R, Williams L, Collier SL, Ahmad N, Boyd A, Reda D, Montor T, Anderson R, Vitek M, et al: Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009, 360:129–139.
5. Home P: Safety of very tight blood glucose control in type 2 diabetes. BMJ 2008, 336(7662):458–9.
6. Bonds DE, Miller ME, Bergenstal RM, et al: The association between symptomatic, severe hypoglycemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ 2010, 340:b1409.
7. Zoungas S, Patel A, Chalmers J, et al. Severe hypoglycemia and risks of vascular events and death. N Engl J Med 2010, 363(15):1410–8.
8. Zammitt NN, Frier BM: Hypoglycemia in type 2 diabetes: pathophysiology, frequency, and effects of different treatment modalities. Diabetes Care 2005, 28(12):2948–2961.
9. DeFronzo RA, Bonadonna RC, Lakoski SG, Alakia BL: Diabetic nephropathy—a review of the natural history, burden, risk factors and treatment. J Natl Med Assoc 2004, 96(11):1445–1454.
10. Wu AY, Kong NC, De Leon FA, Pan CY, Tai TY, Yeung VT, Yoo SJ, Rouillon A, Weir MR: An alarmingly high prevalence of diabetic nephropathy in Asian type 2 diabetic patients: the Microalbuminuria Prevalence (MAP) Study. Diabetologia 2005, 48(1):17–26.
11. Kong AP, So WY, Sato CC, Chan CN, Luk A, Ma RC, Ozaki R, Ng W, Ho CS, Lam CW, Chow CC, Cockram CS, Chan JC, Tong PC: Assessment of glomerular filtration rate in addition to albuminuria is important in managing type II diabetes. Kidney Int 2006, 69(3):383–387.
12. Yang X, So WY, Tong PC, Ma RC, Kong AP, Lam CW, Ho CS, Cockram CS, Ko GT, Chow CC, Wong VK, Chan JC: Development and validation of an all-cause mortality risk score in type 2 diabetes. Arch Intern Med 2008, 168(5):451–457.
13. Kong AP, Yang X, Ko GT, So WY, Chan WB, Ma RC, Ng WY, Chow CC, Cockram CS, Tong PC, Wong Y, Chan JC: Effects of treatment targets on subsequent cardiovascular events in Chinese patients with type 2 diabetes. Diabetes Care 2007, 30(6):953–959.
14. Kong AP, Yang X, Luk A, Ma RC, So WY, Ozaki R, Ting R, Cheung K, Ho CS, Chan MH, Chow CC, Chan JC: Severe hypoglycemia identifies vulnerable patients with type 2 diabetes at risk for premature death and all-site cancer: The Hong Kong Diabetes Registry. Diabetes Care 2014, 37(1):1–8.
15. Piwernetz K, Home PD, Snorgaard O, Antsiferov M, Staehr-Johansen K, Kans M, For the DiabCare Monitoring Group of the St. Vincent Declaration Steering Committee: Monitoring the targets of the St. Vincent declaration and the implementation of quality management in diabetes care: the DiabCare initiative. Diabet Med 1993, 10:371–377.
16. Ma YC, Zuo L, Chen JH, Luo Q, Yu XQ, Li Y, Xu JS, Huang SM, Wang LN, Huang W, Wang M, Xu GB, Wang HY: Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol 2006, 17(10):2937–2944. Epub 2006 Sep 20.
17. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification: Kidney Disease Outcome Quality Initiative. Am J Kidney Dis 2002, 39(5):S1–S246.
18. Li R, Chambless L: Test for additive interaction in proportional hazards models. Ann Epidemiol 2007, 17(3):227–236.
19. Raz I, Riddle MC, Rosenstock J, Buse JB, Inzucchi SE, Home PD, Del Prato S, Pozzilli P, Leslie RD, Chan J, De Fronzo R, Monnier L, Del Prato S: ABCD of glycaemia management in type 2 diabetes: a physician’s digital medicine. Drug Saf 2007, 30(12):979–988.
20. Anderson T, Alfredsson L, Kalberg H, Zdravkovic S, Ahlbom A: Measuring measures of biological interaction. Eur J Epidemiol 2005, 20(7):575–579.
21. Andersson T, Alfredsson L, Kalberg H, Zdravkovic S, Ahlbom A: Measuring measures of biological interaction. Eur J Epidemiol 2005, 20(7):575–579.
22. Andersson T, Alfredsson L, Kalberg H, Zdravkovic S, Ahlbom A: Measuring measures of biological interaction. Eur J Epidemiol 2005, 20(7):575–579.
23. Andersson T, Alfredsson L, Kalberg H, Zdravkovic S, Ahlbom A: Measuring measures of biological interaction. Eur J Epidemiol 2005, 20(7):575–579.
24. Andersson T, Alfredsson L, Kalberg H, Zdravkovic S, Ahlbom A: Measuring measures of biological interaction. Eur J Epidemiol 2005, 20(7):575–579.
25. Raz I, Riddle MC, Rosenstock J, Buse JB, Inzucchi SE, Home PD, Del Prato S, Ferrerini E, Chan JC, Leiter LA, Leroith D, Defrando R, Cefalu WT: Personalized management of hyperglycemia in type 2 diabetes: Reflections from a diabetes care editors’ expert forum. Diabet Care 2013, 36:1779–1786.
26. UKPDS: Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352:837–853.
27. Moen MF, Zhan M, Hsu VD, Walker LD, Einhorn LM, Seliger SL, Fink JC: Frequency of hypoglycemia and its significance in chronic kidney disease. Clin J Am Soc Nephrol 2009, 4(6):1121–1127.
28. Ma RC, Kong AP, Chan N, Tong PC, Chan JC: Drug-induced endocrine and metabolic disorders. Drug Saf 2007, 30(3):215–245.
29. So WY, Chan JC, Yeung VT, Chow CC, Ko GT, Li JK, Cockram CS: Sulphonylurea-induced hypoglycaemia in institutional elderly in Hong Kong. Diabet Med 2002, 19(11):966–968.
30. Luk AO, Yang X, Ma RC, Ng WY, Yu LW, Lau WW, Ozaki R, Chow FC, Kong AP, Tong PC, Chan JC, So W: Association of statin use and development of renal dysfunction in type 2 diabetes—the Hong Kong Diabetes Registry. Diabet Res Clin Pract 2010, 88(3):227–233.
31. Matsuhashi K, van der Velde M, Astor BC, Woodward M, Levey AS, De Jong PE, Coresi J, Garrevoet RT: Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010, 375(9731):2073–2081.
32. Tong PC, Kong AP, So WY, Ng MH, Yang X, Ng MC, Ma RC, Ho CS, Lam CW, Chow CC, Cockram CS, Chan JC: Hematocrit, independent of chronic kidney disease, predicts adverse cardiovascular outcomes in Chinese patients with type 2 diabetes mellitus. *Diabetes Care* 2006, 29(11):2439–2444.
33. So WY, Kong AP, Ma RC, Ozaki R, Szeto CC, Chan NN, Ng V, Ho CS, Lam CW, Chow CC, Cockram CS, Chan JC, Tong PC: Glomerular filtration rate, cardioend point events, and all-cause mortality in type 2 diabetic patients. *Diabetes Care* 2006, 29(9):2046–2052.
34. Fouque D, Pelletier S, Mafa D, Chauveau P: Nutrition and chronic kidney disease. *Kidney Int* 2011, 80(6):348–357.
35. Palesty JA, Dudrick SJ: Cachexia, malnutrition, the refeeding syndrome, and lessons from Goldilocks. *Surg Clin North Am* 2011, 91(3):653–673.
36. Yang X, So WY, Ma RC, Kong AP, Xu G, Chan JC: Diabetes and cancer: the mechanistic implications of epidemiological analyses from the Hong Kong Diabetes Registry. *Diabetes Metab Res Rev* 2012, 28(5):379–87.
37. Seshasai SR, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, Sarwar N, Whincup PH, Mukamal KJ, Gillum RF, Holme I, Njølstad I, Fletcher A, Nilsson P, Lewington S, Collins R, Gudnason V, Thompson SG, Sattar N, Selvin E, Hu FB, Danesh J: Emerging Risk Factors Collaboration: Diabetes mellitus, fasting, and risk of cause-specific death. *N Engl J Med* 2011, 364(8):829–41.
38. Kiyota Y, Schneeweiss S, Glynn RJ, Cannuscio CC, Avorn J, Solomon DH: Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. *Am Heart J* 2004, 148(1):99–104.
39. Birman-Deych E, Waterman AD, Yan Y, Nilasena DS, Radford MJ, Gage BF: Accuracy of ICD-9-CM codes for identifying cardiovascular and stroke risk factors. *Med Care* 2005, 43(5):480–485.

doi:10.1186/1472-6823-14-48

Cite this article as: Kong et al.: Hypoglycaemia, chronic kidney disease and death in type 2 diabetes: the Hong Kong diabetes registry. *BMC Endocrine Disorders* 2014:48.